Chemotherapy in Thymic Neoplasms

  • Pier Franco Conte
  • Fausto Barbieri


Thymic neoplasms are chemotherapy-sensitive tumors with a 30–50% 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).


Clin Oncol Thymic Carcinoma Proc ASCO Japan Clinical Oncology Group Thymic Neoplasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Macchiarini P, Chella A, Ducci F et al (1991) Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68:706–713PubMedCrossRefGoogle Scholar
  2. 2.
    Rea F, Sartori F, Loy M et al (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106(3):543–549PubMedGoogle Scholar
  3. 3.
    Kim ES, Putnam JB Jr, Komaki R et al (2004) A phase II study of a multidisciplinary approach with induction chemotherapy (IC), followed by surgical resection (SR), radiation therapy (RT) and consolidation chemotherapy for unresectable malignant thymoma. Final report. Lung Cancer 44:369–379PubMedCrossRefGoogle Scholar
  4. 4.
    Lucchi M, Ambrogi MC, Duranti L et al (2005) Advanced stage thymomas and thymic carcinomas: Results of multimodality treatments. Ann Thorac Surg 79(6):1840–1844PubMedCrossRefGoogle Scholar
  5. 5.
    Huang J, Rizk N, Park B et al (2007) Recent clinical experience with multimodality therapy in thymic carcinoma. Proc ASCO 2007 (absract 18007)Google Scholar
  6. 6.
    Venuta F, Rendina EA, Pescarmona EO et al (1997) Multimodality treatment of thymoma: A prospective study. Ann Thorac Surg 64:1585–1592PubMedCrossRefGoogle Scholar
  7. 7.
    Venuta F, Rendina EA, De Giacomo T et al (1998) Severe postoperative hemorrhage after neoadjuvant chemotherapy for invasive thymoma. Ann Thorac Surg 66:981–982PubMedCrossRefGoogle Scholar
  8. 8.
    Loehrer PJ Sr, Chen M, Kim K et al (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial. J Clin Oncol 15(9):3093–3099PubMedGoogle Scholar
  9. 9.
    Shin DM, Walsh GL, Komaki R et al (1998) A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med 129(2):100–104PubMedGoogle Scholar
  10. 10.
    Jacot W, Quantin X, Valette S et al (2005) Multimodality treatment program in invasive thymic epithelial tumor. Am J Clin Oncol 28(1):5–7PubMedCrossRefGoogle Scholar
  11. 11.
    Iwasaki Y, Ohsugi S, Takemura Y et al (2002) Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma. Chest 122:2249–2252PubMedCrossRefGoogle Scholar
  12. 12.
    Highley MS, Underhill CR, Parnis FX et al (1999) Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17:2737–2744PubMedGoogle Scholar
  13. 13.
    Hejna M, Haberl I, Raderer M (1999) Nonsurgical management of malignant thymoma. Cancer 85:1871–1884PubMedGoogle Scholar
  14. 14.
    Fornasiero A, Daniele O, Ghiotto C et al (1991) Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68(1):30–33PubMedCrossRefGoogle Scholar
  15. 15.
    Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14(3):814–820PubMedGoogle Scholar
  16. 16.
    Loehrer PJ Sr, Jiroutek M, Aisner S et al (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial. Cancer 91(11):2010–2015PubMedCrossRefGoogle Scholar
  17. 17.
    Kunitoh H, Tamura T, Fukuda H et al (2006) Dose intensive chemotherapy (Cx) in advanced thymoma: Initial report of Japan Clinical Oncology Group trials (JCOG 9605 and 9606) Proc ASCO 2006 (abstract 7080)Google Scholar
  18. 18.
    Loehrer PJ Sr, Kim K, Aisner SC et al (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12(6):1164–1168PubMedGoogle Scholar
  19. 19.
    Loehrer PJ, Yiannoutsos CT, Dropcho S et al (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Proc ASCO 2006 (abstract 7079)Google Scholar
  20. 20.
    Hanna N, Gharpure VS, Abonour R et al (2001) High-dose carboplatin with etoposide in patients with recurrent thymoma: The Indiana University experience. Bone Marrow Transpl 28:435–438CrossRefGoogle Scholar
  21. 21.
    Palmieri G, Montella L, Martignetti A et al (2002) Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94:1414–1420PubMedCrossRefGoogle Scholar
  22. 22.
    Loehrer PJ Sr, Wang W, Johnson DH et al (2004) Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 22:293–299PubMedCrossRefGoogle Scholar
  23. 23.
    Tetsuya O, Horoyuki A, Kato D et al (2004) Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 50:279–282CrossRefGoogle Scholar
  24. 24.
    Farina G, Garassino MC, Gambacorta M et al (2007) Response of thymoma to Cetuximab. Lancet Oncol 8:449–450PubMedCrossRefGoogle Scholar
  25. 25.
    Chuah C, Lim TH, Lim AS et al (2006) Dasatinib induces a response in malignant thymoma. J Clin Oncol 34:56–58CrossRefGoogle Scholar
  26. 26.
    Taguchi T, Suehiro T, Toru K et al (2006) Pleural dissemination of thymoma showing tumor regression after combined corticosteroid and tacrolimus therapy. Eur J Int Med 8:575–577CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Pier Franco Conte
    • 1
  • Fausto Barbieri
    • 1
  1. 1.Department of Oncology and HemathologyUniversity of Modena and Reggio EmiliaModenaItaly

Personalised recommendations